Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and GenoSplice Technology, developers of bioinformatics solutions for analysis of genomic data, have formed a partnership.
The collaboration will provide GenoSplice with access to several Curie-Cancer technology platforms to allow it to continue to improve its services to its clients. GenoSplice will, in turn, be included in Institut Curie research programmes and will benefit from access to the intellectual property generated during the projects.
This agreement will allow GenoSplice to specifically contribute to the development of new products against cancer. The agreement also facilitates better understanding of complex diseases such as cancer through genome mapping.
GenoSplice will use Curie-Cancer’s genomic platform to continue to offer data processing to their primary client base – large pharmaceutical laboratories, biotechnology companies and academic research centres.
The clients use GenoSplice to process the data gathered from high-speed sequencing and/or DNA microarrays, as well as to obtain a better understanding of the biological mechanisms involved with alternative splicing for their R&D projects.
'Participating in research projects with the Institut Curie, which are sometimes multi-party and involve other international research institutes, will put us at the forefront of developments in our areas of interest and will enable us to provide the best possible service to our clients,' said Pierre de la Grange, scientific director and co-founder of GenoSplice.